Answers are grounded in this paper and cite their sources.
Neuropsychiatric disorders have been actively studied for several decades.Many of these disorders were treated by pharmacotherapy, certain forms of psychotherapy, and electroconvulsive therapy.Several classes of drugs with a range of binding selectivities have been discovered and used in the treatment of various central nervous system (CNS) disorders.The earlier drugs had undesired side effects because of their binding to a broad range of neurotransmitters.However, with the advancement of science, there is an increasing understanding of the role of monoamine neurotransmitters in various CNS disorders, which had resulted in the rational design of potent drugs with very selective binding properties.Yet, there are many unanswered questions, and the CNS research is being more actively pursued than ever with newer additional tools such as magnetic resonance imaging (MRI), molecular imaging by positron emission tomography (PET), single-photon emission tomography (SPECT), etc.The goal of this review is to bring together the recent discoveries on selective norepinephrine reuptake inhibitors, developments, and their uses in depression and ADHD.Some of the dual inhibitors of norepinephrine and serotonin transporters have also been included in this review, as these have very similar applications.This paper is dedicated to Prof.
No takes yet. Share an insight, caveat, or question.
Maiti et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: